No. S221038 (Court of Appeal No. A140035) (San Francisco County Super. Ct. J.C.C.P. No. 4748)

IN THE SUPREME COURT OF THE STATE OF CALIFORNIA

Bristol-Myers Squibb Company, *Petitioner*,

v.

FILED

SUPERIOR COURT FOR THE COUNTY OF SAN FRANCISCO, Respondent.

0CT - 3 2014

BRACY ANDERSON, ETAL., Real Parties in Interest. Frank A. McGuire Clerk

Deputy

REPLY IN SUPPORT OF PETITION FOR REVIEW

JEROME B. FALK, JR. (No. 39087)
jerome.falk@aporter.com
SEAN M. SELEGUE (No. 155249)
ARNOLD & PORTER LLP
Three Embarcadero Center, 10th Floor
San Francisco, CA 94111-4024
Telephone: 415.471.3100
Facsimile: 415.471.3400

STEVEN G. READE

pro hac vice pending

DANIEL S. PARISER

pro hac vice pending

ANNA K. THOMPSON

pro hac vice pending

ARNOLD & PORTER LLP

555 Twelfth Street, N.W. Washington, DC 20004-1206

Telephone:

202.942.5000

ANAND AGNESHWAR

pro hac vice pending

ARNOLD & PORTER LLP

399 Park Avenue

New York, NY 10022-4690

Telephone: 212.715.1000

LEA BRILMAYER

pro hac vice pending

Yale Law School
127 Wall Street

New Haven, CT 06520-8215

Telephone: 203.432.0194

JON B. EISENBERG (No. 88278) HORVITZ & LEVY LLP 15760 Ventura Blvd., 18th Floor Encino, CA 91436-3000 Telephone: 818.995.0800

Attorneys for Petitioner Bristol-Myers Squibb Company

TABLE OF CONTENTS

	Page
INTRODUCTION	1
I. THE PETITION IS TIMELY.	1
II. THE ANSWER DOES NOT REBUT BMS'S SHOWING THAT THE OPINION CONFLICTS WITH GOVERNING PRECEDENT AND RAISES AN IMPORTANT QUESTION OF LAW HAVING	
WIDESPREAD IMPLICATIONS.	1
CONCLUSION	6

TABLE OF AUTHORITIES

•	Page(s)
Cases	
Aaron v. Merck & Co., No. CV 05-4073, 2005 WL 5792361 (C.D. Cal. July 26, 2005)	2
Boaz v. Boyle & Co., 40 Cal. App. 4th 700 (1995)	2
Daimler AG v. Bauman, 134 S. Ct. 746 (2014)	3, 4
Dunbar v. Medtronic, Inc., No. CV-14-01529, 2014 WL 3056081 (C.D. Cal. June 25, 2014)	2
Fisher Governor Co. v. Superior Court, 53 Cal. 2d 222 (1959)	2
In re Plavix Prod. Liab. & Mktg. Litig., MDL No. 3:13-cv-2418, slip. op. (D.N.J. Oct. 1, 2014)	3
Shiley Inc. v. Superior Court, 4 Cal. App. 4th 126 (1992)	2
Spirits, Inc. v. Superior Court, 104 Cal. App. 3d 918 (1980)	2
Rules	
CAL. R. CT. 8.490(b)(2) 8.500(e)(1) 8 1105	1 1 4

INTRODUCTION

Whether for tactical reasons or because they have no substantive response to the Petition, the non-resident Plaintiffs¹ have filed a cursory Answer that begins with an erroneous procedural argument and finishes with conclusory assertions unsupported by authority or explanation. Contrary to their contentions, the Petition was timely filed, and presents an important question—arising from an Opinion that conflicts with prior decisions—that this Court should settle.

I.

THE PETITION IS TIMELY.

The non-resident Plaintiffs say that this Petition is untimely. See Answer 4. It is not. Under California Rule of Court 8.500(e)(1), "[a] petition for review must be served and filed within 10 days after the Court of Appeal decision is final in that court." "[D]ecisions in a writ proceeding are final 30 days after the decision is filed" CAL. R. CT. 8.490(b)(2). Accordingly, the decision became final on August 29, 2014, and BMS had ten days after that—until September 8, 2014—to petition for review. BMS timely filed this Petition three days early on September 5, 2014.

11.

THE ANSWER DOES NOT REBUT BMS'S SHOWING THAT THE OPINION CONFLICTS WITH GOVERNING PRECEDENT AND RAISES AN IMPORTANT QUESTION OF LAW HAVING WIDESPREAD IMPLICATIONS.

The non-resident Plaintiffs assert in conclusory fashion that the Petition does not establish grounds for review because "there is no lack of uniformity of decision between

¹ Respondents refer to themselves in their Answer as Real Parties in Interest ("RPI").

California Supreme Court precedent and the Opinion, nor an important question of law to settle." Answer 4. But they do not address, much less rebut, any argument BMS raised in its Petition.

First, the Petition demonstrates that the Opinion conflicts with at least three prior California opinions: Fisher Governor Co. v. Superior Court, 53 Cal. 2d 222 (1959), Spirits, Inc. v. Superior Court, 104 Cal. App. 3d 918 (1980), and Boaz v. Boyle & Co., 40 Cal. App. 4th 700 (1995). See Petition 8-10. It also conflicts with numerous federal cases and with an Illinois court's decision in the Plavix® litigation. See Petition 10, 18-20. The Answer does not mention these cases, much less refute the Petition's showing that the Opinion conflicts with them.

Second, the Answer portrays the Opinion as an "everyday application" of the "substantial connection" test to a "unique fact pattern." Answer 4. But the facts here are not unique and the issues are not ordinary.

The nationwide Plavix® litigation involves a repeated pattern: several thousand plaintiffs, who reside all across the country, concentrated in only a handful of their lawyers' chosen forum states. BMS's writ petition cites numerous examples of similar cases pending in California courts and elsewhere. See Writ Petition 21 n.5. Case law provides yet more examples fitting this fact pattern. See, e.g., Shiley Inc. v. Superior Court, 4 Cal. App. 4th 126 (1992) (heart valve product liability litigation brought by four California plaintiffs and 35 non-residents); Dunbar v. Medtronic, Inc., No. CV-14-01529, 2014 WL 3056081 (C.D. Cal. June 25, 2014) (INFUSE bone graft product liability action brought by one California plaintiff and 28 non-residents); Aaron v. Merck & Co., No. CV 05-4073, 2005 WL 5792361 (C.D. Cal. July 26, 2005) (Vioxx product liability action brought by 38 California plaintiffs and 96 non-residents); see also Amicus Curiae

Letter of Generic Pharmaceutical Association at 4, No. S221038 (Cal. Sept. 24, 2014) (discussing other coordinated proceedings that involve a relatively few number of resident plaintiffs joined with non-resident plaintiffs).

Far from being "unique," the issue raised here affects tens of thousands of product liability claims. Indeed, in the Plavix® litigation alone, it will affect more than 3,000 plaintiffs. In addition to the 575 out-of-state Plaintiffs previously before the trial court, the New Jersey judge overseeing the federal multidistrict litigation recently remanded to California Superior Court 57 cases involving more than 3,000 plaintiffs from 45 states, Puerto Rico and Canada. See In re Plavix Prod. Liab. & Mktg. Litig., MDL No. 3:13-cv-2418, slip. op. at 4 (D.N.J. Oct. 1, 2014);² see also Writ Petition 3 n.1 (Cal. Ct. App. Oct. 22, 2013).

Nor are the issues ordinary. As one of the first appellate decisions in this State to address personal jurisdiction after *Daimler AG v. Bauman*, 134 S. Ct. 746 (2014),³ the Opinion

² As of this filing, the opinion is only available on PACER. BMS will provide the Court with a Westlaw or Lexis citation when available. The MDL Court expressed some discomfort with the way these claims were joined in an attempt to keep them in California state court:

[[]T]he Removal Defendants' position as to the manner in which Plaintiffs here have pled their Complaints, including the joining of numerous potentially non-related claims, raises substantial concerns. . . . In my view, in pharmaceutical cases like the ones here, courts should be steadfast in guarding against plaintiffs' attempts at forum shopping by employing questionable procedural mechanisms, including misjoinder of claims. The question of misjoinder remains in these cases, but will be left to the sound judgment of the state court (*In re Plavix*, slip op. at 27-28).

³ The non-resident Plaintiffs claim that BMS "concedes that the Opinion does not conflict with the holding" in *Daimler*. Answer 5. That is not accurate. Although the Opinion "followed *Daimler*'s literal holding" (Petition 2), it (...continued)

will have enormous importance statewide and nationwide. The Court of Appeal recognized that its ruling went beyond existing specific jurisdiction precedent (App. 32), and certified for publication its 40-page decision. The significance of this case is why it attracted substantial interest from amici curiae on both sides in the Court of Appeal and continues to do so here. See, e.g., Amicus Curiae Brief of American Association for Justice in Support of Real Parties in Interest, No. A140035 (Cal. Ct. App. May 29, 2014); Amicus Curiae Brief of Consumer Attorneys of California Supporting Real Parties in Interest, No. A140035 (Cal. Ct. App. May 23, 2014); Amicus Curiae Brief of Chamber of Commerce in Support of Petitioner, No. A140035 (Cal. Ct. App. Apr. 14, 2014).

Petitioners have delineated at length the reasons warranting review and will not rehash those arguments here. Suffice it to say that the non-resident Plaintiffs do not deny that:

• No California court has previously held that the "substantial connection" necessary to establish specific jurisdiction "need not have any relevance to

nonetheless stands fundamentally at odds with *Daimler*. *Daimler* condemned the exercise of personal jurisdiction over out-of-state companies in the dozens of states where the defendant does business on the basis of general jurisdiction. 134 S. Ct. at 761-62. The Court of Appeal effectively resurrects the pre-*Daimler* regime in which plaintiffs can sue a national manufacturer in virtually any state in which that manufacturer does substantial business through the backdoor of specific jurisdiction. *See* Petition 4-5, 17-20.

⁴ To meet the standards for certification for publication, a Court of Appeal decision should: (1) establish a new rule of law, (2) apply an existing rule of law to a set of facts significantly different from those stated in published opinions, (3) modify, explain, or criticize an existing rule of law, (4) address or create an apparent conflict in the law, (5) involve a legal issue of continuing public interest, or (6) make a significant contribution to legal literature. See CAL. R. CT. 8.1105.

- establishing the plaintiff's claim" (App. 28 (emphasis in original); Petition 13-16);
- The Opinion disregards territorial limits on state court jurisdiction, contrary to decisional law not only in the Due Process area but also Commerce Clause and Full Faith and Credit jurisprudence (Petition 11-13); and
- The Opinion is not limited to the pharmaceutical industry. It applies with equal force to any company that does business in California (Petition 1, 17, 20).

Finally, the non-resident Plaintiffs dismiss the burdens on California courts and jurors as "not a factor statutorily identified that the Supreme Court must consider when reviewing a petition." Answer 6. But they do not explain why such sweeping impacts on courts and jurors would not fit this Court's criteria for review.

CONCLUSION

For the foregoing reasons and those stated in the Petition for Review, this Court should grant review.

DATED: October 3, 2014

Respectfully,

ARNOLD & PORTER LLP JEROME B. FALK, JR. SEAN M. SELEGUE ANAND AGNESHWAR STEVEN G. READE DANIEL S. PARISER ANNA K. THOMPSON

LEA BRILMAYER

HORVITZ & LEVY LLP JON B. EISENBERG

SEAN M. SELEGUE

Attorneys For Petitioner Bristol-Myers Squibb Company

CERTIFICATE OF COMPLIANCE PURSUANT TO CAL. R. CT. 8.504(d)(1)

Pursuant to California Rule of Court 8.504(d)(1), and in reliance upon the word count feature of the software used, I certify that the attached **Reply in Support of Petition for Review** contains 1,348 words, exclusive of those materials not required to be counted under Rule 8.504(d)(3).

DATED: October 3, 2014

SEAN M. SELEGUE

PROOF OF SERVICE

I am a resident of the State of California and over the age of eighteen years, and not a party to the within action; my business address is Three Embarcadero Center, 10th Floor, San Francisco, California 94111-4024. On October 3, 2014, I served the following document(s) described as REPLY IN SUPPORT OF PETITION FOR REVIEW on the interested parties in this action by placing a true copy thereof enclosed in a sealed envelope addressed to each as follows:

Hunter J. Shkolnik John Lytle Kelly A. McMeekin NAPOLI BERN RIPKA SHKOLNIK & ASSOCIATES LLP 525 S. Douglas Street, Suite 260 El Segundo, CA 90245 Attorneys for Real Parties in Interest

William Audet Joshua C. Ezrin Mark E. Burton, Jr. AUDET & PARTNERS LLP 221 Main Street, Suite 1460 San Francisco, CA 94105 Attorneys for Real Parties in Interest

Donald S. Edgar Rex Grady THE EDGAR LAW FIRM 408 College Avenue Santa Rosa, CA 95401 Attorneys for Interested Parties Mattie Bryant et al.

Charles A. Samuels
Timothy J. Slattery
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY AND POPEO, P.C.
701 Pennsylvania Avenue, N.W.
Washington, DC 20004

Attorneys for *Amicus Curiae* Association of
Home Appliance
Manufacturers

Charles A. Bird MCKENNA LONG & ALDRIDGE LLP 600 West Broadway, Ste. 2600 San Diego, CA 92101 Attorneys for *Amicus Curiae* DRI-The Voice
of the Defense Bar

Steven A. Ellis GOODWIN PROCTOR LLP 601 S. Figueroa Street, 41st Floor Los Angeles, CA 90017 Attorneys for Amicus Curiae Generic Pharmaceutical Association Anne Marie Mortimer Franjo M. Dolenac HUNTON & WILLIAMS LLP 550 South Hope Street, Ste. 2000 Los Angeles, CA 90071

David C. Spangler Consumer Healthcare Products Association 1625 Eye Street, N.W., Suite 600 Washington, DC 20006

Clerk of the Court San Francisco County Superior Court 400 McAllister Street San Francisco, CA 94102

Hon. John Munter San Francisco County Superior Court Department 305 400 McAllister Street San Francisco, CA 94102

Clerk of the Court First District Court of Appeal, Division 2 350 McAllister Street San Francisco, CA 94102

I am readily familiar with Arnold & Porter's practice for collection and processing of correspondence for mailing with the United States Postal Service. I know that the correspondence is deposited with the United States Postal Service on the same day this declaration was executed in the ordinary course of business. I know that the envelope was sealed and, with postage thereon fully prepaid, placed for collection and mailing on this date, following ordinary business practices, in the United States mail at San Francisco, California.

I declare under penalty of perjury that the foregoing is true and correct. Executed at San Francisco, California on October 3, 2014.

Attorneys for *Amici Curiae* National
Association of
Manufacturers et al.

Senior V.P., Policy, General Counsel & Secretary for Amicus Curiae Consumer Healthcare Products Association